![logo](/logos/CYTK.webp)
Cytokinetics, Incorporated
NASDAQ:CYTK
54.09 (USD) • At close September 6, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Cytokinetics, Incorporated |
Symbool | CYTK |
Munteenheid | USD |
Prijs | 54.09 |
Beurswaarde | 6,364,229,400 |
Dividendpercentage | 0% |
52-weken bereik | 25.98 - 110.25 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Robert I. Blum |
Website | https://www.cytokinetics.com |
An error occurred while fetching data.
Over Cytokinetics, Incorporated
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)